Alexion Pharmaceuticals, Inc. company logo

# 1st Gen Model Alexion Pharmaceuticals, Inc. Pharmaceutical preparations

Subscribe >> Deal exit on
Oct. 23, 2017
Deal entry on
Oct. 23, 2017
1.67%Expected margin
58.11% successful of 74 deals
$135.20 Last close price
at 23-oct-2017

ALXN

Model's trade recommendations 3.99% Return for period

0.52% Annual return

$31.03B Market Cap

β 1.39  

ALXN

Model (following trade recommendations)

ALXN

Underlying stock

S&P 500

Index
Return for period 3.99%
-3.22%
1.78%
52wk return 23.29%
11.18%
16.82%
52wk Range
97.70—146.69
2000.54—2399.63
Sortino ratio 0.30
Sharpe ratio 0.15
Norm. RMSE 0.24%
Downside risk 15.91%
Volatility 32.84%
  • STRONG BUY Analysts consensus recommendation

Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company's lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system induces undesired inflammation in the human body. These candidates are designed to block components of the human immune system which cause undesired inflammation while allowing beneficial components of the immune system to remain functional.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Alexion Pharmaceuticals, Inc. (ALXN) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 2, 2015.

Market data for ALXN model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 213M
P/E 29.02
Shares Outstanding 223M
% Held by Insiders 4.35%
% Held by Institutions 94.15%
EPS (last reported FY) $3.78
EPS (last reported Q) $1.31
EPS, estimated (last reported Q) $1.08
Total revenues $3 B
Net income $0 B